Tyra Biosciences Inc. has reported the first Phase 2 results from SURF302 evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, producing a dataset that simultaneously supports further development and exposes uncertainty around how strongly the drug performs when tumor burden is higher. At the selected 60 mg once-daily dose, 11 of 14 efficacy-evaluable patients achieved an objective response, while eight of 14 had a complete response at the three-month assessment.
The most favorable result came from the smaller subgroup with a single marker lesion. All eight patients treated at 60 mg responded, while five achieved complete responses at three months and six had achieved a complete response as their best overall response by the August 31 data cutoff. Tyra Biosciences believes that lower-burden population most closely resembles the adjuvant setting it intends to pursue in a registrational Phase 3 study after visible tumors have been surgically removed.
Investors were less persuaded by the initial dataset than management. Tyra Biosciences shares fell 17.7% on September 9 after the results were released, reflecting concern that the broader complete response rate was below the level some investors had expected and that activity appeared weaker among patients with multiple lesions. The stock subsequently recovered part of the decline before returning to about $22.01 on September 11, leaving the market clearly divided over whether the subgroup strategy will translate into a successful pivotal program.
What did SURF302 actually show at the 60 mg dabogratinib dose?
As of the August 31 cutoff, 26 patients were evaluable for efficacy across two dose cohorts. Fourteen received 60 mg once daily and 12 received 50 mg once daily. At 60 mg, the overall response rate was 79%, with 11 of 14 patients responding, while the three-month complete response rate was 57%, representing eight of 14 patients.
One patient initially classified with a partial response at three months converted to a complete response at six months, increasing the best overall complete response rate at 60 mg to 64%. At the 50 mg dose, eight of 12 participants responded, producing an overall response rate of 67%, while four of 12 achieved a complete response.
Those headline figures are encouraging but less dramatic than the performance in patients with only one marker lesion. Among eight single-lesion patients treated with 60 mg, the overall response rate was 100%. Five had complete responses at three months and a sixth converted from partial to complete response at six months, producing a best overall complete response rate of 75%.
The small subgroup is central to Tyra Biosciences’ strategy because the company argues that minimal visible disease more closely approximates an adjuvant setting after transurethral resection. Six of the seven nonresponding patients across the broader evaluated population reportedly had multiple marker lesions, suggesting that higher tumor burden may require greater drug exposure or a different treatment strategy.
That interpretation is plausible, but it remains a subgroup observation derived from very small numbers. Eight patients cannot establish how reliably the response pattern will reproduce in a registrational population, and the Phase 3 study will need to be designed around endpoints relevant to recurrence prevention rather than simply shrinking intentionally retained marker lesions.
Why is Tyra Biosciences focusing Phase 3 development on the adjuvant setting?
Low-grade intermediate-risk non-muscle invasive bladder cancer is characterized less by immediate mortality risk than by repeated recurrence and the burden of continual surveillance and treatment. Patients commonly undergo transurethral resection to remove visible tumors, followed by cystoscopic monitoring and, for some patients, intravesical therapy delivered directly into the bladder.
Tyra Biosciences argues that treatment burden contributes to underuse of adjuvant therapy. The company estimates that around 70% of patients in this risk category do not receive a preventive intravesical treatment intended to lower recurrence, leaving many on surveillance until another tumor appears.
A once-daily oral treatment could theoretically change that trade-off if it reduces recurrence while remaining tolerable enough for prolonged use. Patients would avoid repeated catheter-based drug administration, and community urologists could potentially prescribe treatment after surgical removal of the tumor.
This is why the single-marker lesion subgroup matters disproportionately to the company’s pivotal strategy. Marker-lesion studies intentionally leave a defined tumor behind so investigators can measure direct antitumor activity. An adjuvant Phase 3 trial, by contrast, would begin after visible disease has been removed, meaning the therapeutic task is suppressing microscopic residual disease and delaying recurrence.
The biological burden in those settings is different. A drug that does not reliably eradicate multiple measurable tumors could still succeed in preventing recurrence after surgery if systemic exposure is sufficient to suppress small residual FGFR3-driven clones. That hypothesis must be demonstrated prospectively rather than inferred from the eight-patient subgroup.
Why does targeting FGFR3 make biological sense in low-grade non-muscle invasive bladder cancer?
Alterations activating fibroblast growth factor receptor 3 are common in low-grade urothelial tumors, making FGFR3 one of the most compelling molecular drivers in this particular bladder-cancer population. Dabogratinib, previously known as TYRA-300, is designed as a selective oral FGFR3 inhibitor intended to suppress signaling from altered receptor forms while reducing activity against other FGFR family members.
Selectivity matters because earlier FGFR inhibitors have demonstrated toxicities associated with broader pathway inhibition, including hyperphosphatemia, ocular effects and nail changes. Such adverse effects may be acceptable in advanced metastatic cancer when treatment alternatives are limited, but the tolerance threshold is considerably lower in patients with non-muscle invasive low-grade disease who may otherwise be managed with local therapy and surveillance.
Tyra Biosciences therefore needs dabogratinib to combine meaningful antitumor activity with an unusually clean chronic-use profile. The initial SURF302 safety data are encouraging on that front. Across 44 patients treated at either 50 mg or 60 mg, most treatment-emergent adverse events were Grade 1 or Grade 2, and no Grade 4 or Grade 5 events were reported.
Grade 3 treatment-related adverse events occurred in two patients, both in the 50 mg cohort, while none were reported at 60 mg. Tyra also reported no clinically significant hyperphosphatemia, nail toxicity or ocular toxicity. The most frequently reported events at 60 mg included fatigue, diarrhea and dry eye, while transaminase elevations occurred in fewer than 10% of patients.
These findings support further chronic-dosing evaluation, but the safety database remains small. Longer treatment duration and a larger Phase 3 population will be necessary to identify uncommon toxicities and determine whether low-grade adverse effects become burdensome enough to affect adherence.
What does the exposure-response analysis suggest about patients with multiple tumors?
Tyra Biosciences found a preliminary relationship between drug exposure and response. Across the 50 mg and 60 mg cohorts, patients whose steady-state exposure exceeded the company’s predefined area-under-the-curve threshold produced an overall response rate of 86%, compared with 58% among those below that exposure level.
The relationship appeared particularly relevant among patients with multiple marker lesions. That observation has prompted Tyra Biosciences to add a 70 mg once-daily cohort to investigate whether higher exposure can improve the drug’s ablative activity in patients with greater visible disease burden.
Dose escalation creates a classic development trade-off. Greater exposure could increase antitumor activity, but it could also erode the favorable tolerability profile that makes an oral chronic treatment attractive. The absence of major class-associated toxicities at 60 mg does not guarantee that 70 mg will behave similarly.
The company is therefore effectively developing two potential uses from the same Phase 2 study. The 60 mg dose is being positioned for an adjuvant Phase 3 setting where tumor burden is minimal after surgery, while the higher dose could eventually support an ablative approach in patients with measurable disease if activity improves without unacceptable toxicity.
That branching strategy is scientifically reasonable, but it also increases execution complexity. Regulators will need to agree that the selected dose, study population and endpoint adequately test each intended use, and the program may require different evidence packages if Tyra eventually seeks more than one clinical indication.
Why did the market punish Tyra Biosciences despite the favorable subgroup data?
Tyra Biosciences shares dropped nearly 18% on the day of the SURF302 disclosure, closing at $22.01 after trading above $26 immediately before the results. The sell-off reflected the market’s tendency to emphasize the broader complete response result rather than management’s interpretation of the single-lesion subgroup.
The 57% complete response rate at three months in the 60 mg all-evaluable cohort was below some investor expectations, particularly given optimism that selective FGFR3 inhibition could produce very high response rates in molecularly selected low-grade disease. The presence of several partial responses and nonresponders in patients with multiple lesions reinforced concern about whether systemic oral exposure is sufficient to eradicate larger visible tumor burden.
The following session brought a 6.95% rebound to $23.54, but shares fell another 6.5% on September 11 to finish at $22.01. That volatile sequence suggests investors are still working through a dataset whose clinical interpretation depends heavily on the setting in which the drug will ultimately be tested.
Tyra Biosciences’ argument is that the market is applying an ablative benchmark to a program whose near-term commercial target will be adjuvant recurrence prevention. That distinction may ultimately prove correct, but the company will have to demonstrate it in a Phase 3 study rather than through post hoc interpretation of the Phase 2 subgroup.
What needs to happen before dabogratinib can become a registrational bladder cancer program?
Tyra Biosciences plans to complete enrollment of the 60 mg cohort, begin testing 70 mg in the higher-burden setting and engage regulators on the design and dose selection for an adjuvant Phase 3 study. Those discussions will be important because a recurrence-prevention trial requires different endpoints and follow-up from a marker-lesion response study.
Duration will be central. In a disease defined by repeated recurrence, demonstrating that treatment merely delays a lesion for several months may not be enough. A pivotal program will need to show a durable and clinically meaningful reduction in recurrence while preserving the favorable tolerability needed for extended oral treatment.
The initial durability signals remain early. Five patients with three-month complete responses who had reached six-month assessment remained in response, and the first patient enrolled continued in complete response through 12 months. Those observations are promising but too limited to establish the durability profile of the drug.
SURF302 therefore has not produced a simple positive or negative answer. It has shown clear oral activity against FGFR3-altered low-grade bladder tumors and a potentially attractive safety profile, while revealing that tumor burden and drug exposure may strongly influence response. The Phase 3 opportunity rests on whether the exceptional small subgroup of low-burden patients is genuinely representative of the postoperative population Tyra Biosciences intends to treat, which is now the key question separating a potentially differentiated oral therapy from another encouraging early-stage oncology signal.
